GLP-1 RAs, primarily used in treating diabetes and obesity, exhibit beneficial cardiovascular effects that intersect indirectly with RAAS signaling pathways [80]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.